Phase 3 Trial Win and 130% Takeover Premium Lift Rare Blood-Disease Stocks

Two unrelated announcements brought rare blood-disease stocks into focus Monday: a company reported that its pivotal Phase 3 trial met every primary endpoint, while another announcement involved a 130% takeover premium. The provided text does not identify the companies or transaction terms.